Showing 6001-6010 of 7027 results for "".
- Researchers Assess Tools to Measure QoL Impact of Skin Conditionshttps://practicaldermatology.com/news/researchers-assess-tools-to-measure-qol-impact-of-skin-conditions/2457827/Boston University School of Medicine researchers have set out to find the best tool to measure the impact of skin coniditons on patients' quality of life. Several dermatology and disease-specific tools have been developed to measure the impact of skin disease including the widel
- FDA Approves Label Update for Cimzia Addressing Low Risk of Fetal Exposurehttps://practicaldermatology.com/news/fda-approves-label-update-for-cimzia-addressing-low-risk-of-fetal-exposure/2457828/The FDA has approved a label update that includes pharmacokinetic data showing negligible to low transfer of Cimzia® (certolizumab pegol) through placenta and minimal transfer to breast milk fr
- EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challengehttps://practicaldermatology.com/news/epigencare-named-as-johnson-johnson-innovation-finalist-in-skincare-challenge/2457829/EpigenCare Inc., a personalized skincare startup company, is a finalist in Johnson & Johnson Innovation’s Digital Beauty Quickfire Challenge. The Challenge
- Sun Pharma: FDA Approves Ilumya for Adult Psoriasishttps://practicaldermatology.com/news/sun-pharma-fda-approves-ilumya-for-adult-psoriasis/2457831/The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya selectively binds to the p19 subunit of IL-23 a
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep
- Newborn Skin May Pave the Way Toward New Eczema Lotionhttps://practicaldermatology.com/news/newborn-skin-may-pave-the-way-for-new-eczema-lotion/2457844/Newborns emerge from the womb covered with a waxy substance called the vernix, which protects their skin from drying, and researchers have begun to realize that the vernix also helps babies adapt to life outside the womb by stimulating cells in the skin to make water-resistant lipid molecules.
- Research Shines Light on Why People Experience AD in Winterhttps://practicaldermatology.com/news/research-shines-light-on-why-people-experience-ad-in-winter/2457845/New research shows that the skin barrier is affected by climatic and seasonal changes. In tests of skin on 80 adults, the levels of breakdown products of filaggrin changed between winter and summer on the cheeks and h
- CareCredit Moves Into Day and Med Spa Marketshttps://practicaldermatology.com/news/carecredit-moves-into-day-and-med-spa-markets/2457847/CareCredit is expanding into the day and medical spa markets. As part of this new program, CareCredit partnered with both the American Med Spa Association and the Spa Industry Association to bring the benefits of CareCredit to their practices. Providers can now offer clients acces
- Episciences Launches New Eczema Creamhttps://practicaldermatology.com/news/episciences-launches-new-eczema-cream/2457851/Episciences, Inc. introduced a new Epionce Renewal Calming Cream, a formula that helps soothe as it replenishes moisture in the skin barrier. Renewal Calming Cream helps relieve the most stubborn symptoms associated with eczema. Ideal for patients with eczema and very dry, sensitive skin, t
- Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2018 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/calling-all-students-ortho-dermatologics-now-accepting-applications-for-the-2018-aspire-higher-scholarship-program/2457855/Ortho Dermatologics is accepting applications for the 2018 Aspire Higher scholarship program for students who have been affected by dermatologic conditions. Through the program, nine students will receive a scholarship of $10,000. The